208 related articles for article (PubMed ID: 16397286)
1. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
3. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region.
Tzanakaki G; Mastrantonio P
Int J Antimicrob Agents; 2007 Jun; 29(6):621-9. PubMed ID: 17368858
[TBL] [Abstract][Full Text] [Related]
4. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of meropenem.
Nicolau DP
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
[TBL] [Abstract][Full Text] [Related]
7. Bacterial profile and clinical outcome of childhood meningitis in rural Yemen: a 2-year hospital-based study.
Al Khorasani A; Banajeh S
J Infect; 2006 Oct; 53(4):228-34. PubMed ID: 16434101
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
11. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.
Goldstein SL; Murry DJ; May S; Aleksic A; Sowinski KM; Blaney S
Pediatr Nephrol; 2001 Dec; 16(12):1015-8. PubMed ID: 11793091
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Paediatr Drugs; 2006; 8(2):131-8. PubMed ID: 16608373
[TBL] [Abstract][Full Text] [Related]
13. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
14. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
[TBL] [Abstract][Full Text] [Related]
18. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of meropenem in burn patients.
Doh K; Woo H; Hur J; Yim H; Kim J; Chae H; Han S; Yim DS
J Antimicrob Chemother; 2010 Nov; 65(11):2428-35. PubMed ID: 20817742
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.
Robatel C; Decosterd LA; Biollaz J; Eckert P; Schaller MD; Buclin T
J Clin Pharmacol; 2003 Dec; 43(12):1329-40. PubMed ID: 14615469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
